Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:51:58 UTC |
---|
HMDB ID | HMDB0015388 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Lapatinib |
---|
Description | Lapatinib, also known as GW 572016 or tykerb, belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. Lapatinib is a very strong basic compound (based on its pKa). Pharmaceutical company GlaxoSmithKline (GSK) markets the drug under the propriety names Tykerb (mostly U.S.) and Tyverb (mostly Europe and Russia). It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2). Like sorafenib, lapatinib is a protein kinase inhibitor shown to decrease tumor-causing breast cancer stem cells. Phase III study designed to assess lapatinib in combination with chemotherapy for advanced HER2-positive gastric cancer in 2013 failed to meet the primary endpoint of improved overall survival (OS) against chemotherapy alone. Secondary endpoints of the randomized, double-blinded study, were progression-free survival (PFS), response rate and duration of response. The outcome of this study resulted in a somewhat complex and rather specific initial indication for lapatinib—use only in combination with capecitabine for HER2-positive breast cancer in women whose cancer have progressed following previous chemotherapy with anthracycline, taxanes and trastuzumab. |
---|
Structure | CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1 InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) |
---|
Synonyms | Value | Source |
---|
GW 572016 | ChEBI | N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine | ChEBI | N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine | ChEBI | Tykerb | ChEBI | N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine | Generator | N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine | Generator | FMM | HMDB | GW572016 | HMDB | Lapatinib ditosylate | HMDB | Lapatinib tosilate hydrate | HMDB | N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine | HMDB |
|
---|
Chemical Formula | C29H26ClFN4O4S |
---|
Average Molecular Weight | 581.058 |
---|
Monoisotopic Molecular Weight | 580.134731942 |
---|
IUPAC Name | N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine |
---|
Traditional Name | lapatinib |
---|
CAS Registry Number | 388082-78-8 |
---|
SMILES | CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1 |
---|
InChI Identifier | InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) |
---|
InChI Key | BCFGMOOMADDAQU-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazanaphthalenes |
---|
Sub Class | Benzodiazines |
---|
Direct Parent | Quinazolinamines |
---|
Alternative Parents | |
---|
Substituents | - Quinazolinamine
- Phenoxy compound
- Aniline or substituted anilines
- Phenol ether
- Aralkylamine
- Halobenzene
- Fluorobenzene
- Chlorobenzene
- Aminopyrimidine
- Alkyl aryl ether
- Imidolactam
- Benzenoid
- Pyrimidine
- Monocyclic benzene moiety
- Aryl halide
- Aryl fluoride
- Aryl chloride
- Heteroaromatic compound
- Sulfonyl
- Sulfone
- Furan
- Oxacycle
- Azacycle
- Secondary amine
- Ether
- Secondary aliphatic amine
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organofluoride
- Organochloride
- Organohalogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.022 g/L | Not Available | LogP | 5.4 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Lapatinib,1TMS,isomer #1 | C[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)C3=C2)O1 | 5016.2 | Semi standard non polar | 33892256 | Lapatinib,1TMS,isomer #1 | C[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)C3=C2)O1 | 4670.3 | Standard non polar | 33892256 | Lapatinib,1TMS,isomer #1 | C[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)C3=C2)O1 | 6791.7 | Standard polar | 33892256 | Lapatinib,1TMS,isomer #2 | C[Si](C)(C)N(C1=CC=C(OCC2=CC=CC(F)=C2)C(Cl)=C1)C1=NC=NC2=CC=C(C3=CC=C(CNCCS(C)(=O)=O)O3)C=C12 | 4749.0 | Semi standard non polar | 33892256 | Lapatinib,1TMS,isomer #2 | C[Si](C)(C)N(C1=CC=C(OCC2=CC=CC(F)=C2)C(Cl)=C1)C1=NC=NC2=CC=C(C3=CC=C(CNCCS(C)(=O)=O)O3)C=C12 | 4594.4 | Standard non polar | 33892256 | Lapatinib,1TMS,isomer #2 | C[Si](C)(C)N(C1=CC=C(OCC2=CC=CC(F)=C2)C(Cl)=C1)C1=NC=NC2=CC=C(C3=CC=C(CNCCS(C)(=O)=O)O3)C=C12 | 6584.8 | Standard polar | 33892256 | Lapatinib,2TMS,isomer #1 | C[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(N(C4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)[Si](C)(C)C)C3=C2)O1 | 4735.9 | Semi standard non polar | 33892256 | Lapatinib,2TMS,isomer #1 | C[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(N(C4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)[Si](C)(C)C)C3=C2)O1 | 4809.5 | Standard non polar | 33892256 | Lapatinib,2TMS,isomer #1 | C[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(N(C4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)[Si](C)(C)C)C3=C2)O1 | 6089.0 | Standard polar | 33892256 | Lapatinib,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)C3=C2)O1 | 5229.2 | Semi standard non polar | 33892256 | Lapatinib,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)C3=C2)O1 | 4929.4 | Standard non polar | 33892256 | Lapatinib,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)C3=C2)O1 | 6707.0 | Standard polar | 33892256 | Lapatinib,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=CC=C(OCC2=CC=CC(F)=C2)C(Cl)=C1)C1=NC=NC2=CC=C(C3=CC=C(CNCCS(C)(=O)=O)O3)C=C12 | 4989.0 | Semi standard non polar | 33892256 | Lapatinib,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=CC=C(OCC2=CC=CC(F)=C2)C(Cl)=C1)C1=NC=NC2=CC=C(C3=CC=C(CNCCS(C)(=O)=O)O3)C=C12 | 4827.1 | Standard non polar | 33892256 | Lapatinib,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C1=CC=C(OCC2=CC=CC(F)=C2)C(Cl)=C1)C1=NC=NC2=CC=C(C3=CC=C(CNCCS(C)(=O)=O)O3)C=C12 | 6460.6 | Standard polar | 33892256 | Lapatinib,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(N(C4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)[Si](C)(C)C(C)(C)C)C3=C2)O1 | 5150.7 | Semi standard non polar | 33892256 | Lapatinib,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(N(C4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)[Si](C)(C)C(C)(C)C)C3=C2)O1 | 5266.3 | Standard non polar | 33892256 | Lapatinib,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(CCS(C)(=O)=O)CC1=CC=C(C2=CC=C3N=CN=C(N(C4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)[Si](C)(C)C(C)(C)C)C3=C2)O1 | 5994.6 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Lapatinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-0pb9-6920550000-7316e856fd5ec8e04f07 | 2017-09-01 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib LC-ESI-qTof , Positive-QTOF | splash10-00lr-0009070000-0d55ba750eaa2fb12020 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib , positive-QTOF | splash10-00lr-0009070000-0d55ba750eaa2fb12020 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib , positive-QTOF | splash10-0ab9-0649800000-87742edfe3489dab4ac8 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib 30V, Positive-QTOF | splash10-001i-0002090000-49e599088394c442e60b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib 40V, Positive-QTOF | splash10-014i-0009020000-1e12983abcdd66482af3 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib 10V, Positive-QTOF | splash10-001i-0000090000-f080a7f403cbfd88c590 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib 20V, Positive-QTOF | splash10-001i-0000090000-e1a1377443b8f411d997 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib 50V, Positive-QTOF | splash10-014i-0009000000-0b1867dee117396c1949 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lapatinib 10V, Positive-QTOF | splash10-001i-0000090000-d725217276a0f9a7e793 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 10V, Positive-QTOF | splash10-001i-0100290000-631c05424fb5cef349db | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 20V, Positive-QTOF | splash10-0a5i-1701890000-169201e0014b0f4031fc | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 40V, Positive-QTOF | splash10-0a4i-6922200000-21ac033aa8e06fb42b19 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 10V, Negative-QTOF | splash10-004i-5100190000-854bae0cfc77e5929d1e | 2016-08-04 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 20V, Negative-QTOF | splash10-004i-9100110000-7b6eac51a2b17a8a0213 | 2016-08-04 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 40V, Negative-QTOF | splash10-004i-9100000000-16d9d0819f6dca47cd5c | 2016-08-04 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 10V, Positive-QTOF | splash10-001i-0000290000-c15d2a8b4702b6befdbd | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 20V, Positive-QTOF | splash10-001i-0001490000-80635a463a3e3328f17b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 40V, Positive-QTOF | splash10-0pbj-2119400000-10638e7b757119205a69 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 10V, Negative-QTOF | splash10-004i-0000090000-9043926cc3ed698dc68e | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 20V, Negative-QTOF | splash10-03fr-1109630000-a046bbec44d7c31559d0 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lapatinib 40V, Negative-QTOF | splash10-0059-9204010000-e84077eb1512ec5949ba | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Burris HA 3rd: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9 Suppl 3:10-5. [PubMed:15163842 ]
- Johnston SR, Leary A: Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006 Jul;42(7):441-53. [PubMed:16894399 ]
- Tevaarwerk AJ, Kolesar JM: Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029. [PubMed:20110044 ]
- Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. [PubMed:18803986 ]
- Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005 Aug 10;23(23):5305-13. Epub 2005 Jun 13. [PubMed:15955900 ]
- Nelson MH, Dolder CR: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother. 2006 Feb;40(2):261-9. Epub 2006 Jan 17. [PubMed:16418322 ]
- Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. [PubMed:17192538 ]
|
---|